(VIANEWS) - The Market ended the session with BIOSENIC (BIOS.BR) rising 14.55% to €0.04 on Tuesday while BEL 20 slid 1.09% to €3,675.52.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €7.53.
PE Ratio
BIOSENIC has a trailing twelve months price to earnings ratio of 0.01. Meaning, the purchaser of the share is investing €0.01 for every euro of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC's stock is considered to be overbought (>=80).
Volume
Today's last reported volume for BIOSENIC is 725386 which is 29.64% below its average volume of 1030980.
More news about BIOSENIC (BIOS.BR).